Full-Time
Confirmed live in the last 24 hours
Develops AI-optimized AAV vectors for gene therapy
Mid, Senior
Belmont, MA, USA
Strong preference for candidates based in NYC or Greater Boston areas for occasional in-person engagements.
Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, and Dyno's AI technology enhances their design and optimization, potentially increasing the effectiveness of gene therapies. The company collaborates with major pharmaceutical and biotech firms, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike its competitors, Dyno leverages proprietary AI technology to streamline the creation of AAV vectors, which sets it apart in the biotech field. The goal of Dyno Therapeutics is to improve gene therapy outcomes through optimized delivery systems, ultimately contributing to better treatment options for patients.
Company Stage
Series A
Total Funding
$106M
Headquarters
Watertown, Massachusetts
Founded
2018
Help us improve and share your feedback! Did you find this helpful?